10 results about "Gabapentin enacarbil" patented technology

This invention provides a drug related to lung injury and its application, the drug comprising gabapentin and / or pharmaceutically acceptable salts of gabapentin; the drug reduces the levels of MPO and NOX2 in lung tissue; the application is for the preparation of formulations for the prevention or treatment of lung injury using gabapentin and / or pharmaceutically acceptable salts of gabapentin, or for the study of the mechanism of lung injury caused by surgery; the study is related to manufacturing and application in industry; the drug can prevent or treat damage caused by lung interruption and re-inflation during lung surgery, and has good application prospects in industry.

The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.

The present disclosure provides methods of determining whether or not to administer a subject gabapentin, said method comprising assessing the genetic profile of a subject considered for a gabapentin-based therapy and determining, on the basis of the genetic profile, whether or not to administer the subject gabapentin.

The present invention relates to use of botulinum toxin type E for preventing or treating neuropathic pain, and specifically, to a pharmaceutical composition comprising botulinum toxin type E for preventing or treating neuropathic pain, and a surgical operation analgesic comprising botulinum toxin type E as an active ingredient. The botulinum toxin type E of the present invention has an analgesic effect by significantly inhibiting neuropathic pain, and, after a single administration, the botulinum toxin type E of the present invention can alleviate side effects and provide an analgesic effect superior to that of Gabapentin, which is a conventional analgesic used for treating neuropathic pain, in mechanical allodynia caused by mandibular alveolar nerve injury. In addition, the botulinum toxin type E of the present invention has a short duration of analgesic action in the body after administration so as to enable faster recovery and rehabilitation than after administration of botulinum toxin type A, and thus can be effectively used for treatment of neuropathic pain.

The invention belongs to the field of biological medicine, and discloses an AER270 diagnosis and treatment prodrug with hypochlorous acid response characteristic as well as a preparation method and application thereof, the AER270 diagnosis and treatment prodrug has a structure as shown in a general formula I. Based on a core structure of methylene blue (MB), gamma-aminobutyric acid (GABA), gabapentin or aminopropanol is used as a connecting chain, and is coupled with an AQP4 inhibitor AER270 through an ester bond or an ether bond, so that the prodrug is prepared. According to the present invention, the HOCl specific activation rupture release active molecules AER270 and GABA or gabapentin is achieved, the penetrability on the blood brain barrier and the selective treatment on the cerebral apoplexy focus are enhanced, the reduced methylene blue molecule is released, the cerebral apoplexy focus can be specifically lightened, and the diagnosis and treatment integration is achieved.

This invention belongs to the field of pharmaceutical technology, specifically relating to soluble gabapentin microneedle patches, their preparation methods, and applications. The microneedles provided by this invention are prepared by negative pressure centrifugation using gabapentin, hyaluronic acid, anesthetic, and water in a specific ratio. These microneedles can penetrate the stratum corneum of the skin, rapidly dissolving and releasing the drug within 10 minutes, effectively solving the problems of slow onset and low bioavailability in traditional drug administration. They also possess excellent mechanical strength and safety, with no skin irritation or organ toxicity, and are specifically designed to relieve or treat symptoms of stress, anxiety, fear, and epilepsy, providing sedation, adjunctive analgesia, and emotional calming effects, significantly improving the convenience and compliance of drug administration.

The present invention relates to a new co-crystal of Gabapentin, Ketoprofen and Lysine, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and / or inflammation.

The present disclosure relates to an industrially feasible and economically viable process for preparation of Gabapentin of formula (I) which is shown below: (I)

The invention relates to the technical field of biological medicines, and provides application of a BCAA inhibitor in preparation of medicines for inhibiting, preventing, relieving or treating mutant leukemia aiming at the problems of high drug resistance, high recurrence rate and limited treatment effect in treatment of DNMT3A mutant AML patients at present. The BCAA inhibitor is gabapentin and / or cytarabine arabinoside. Experiments prove that gabapentin has a treatment effect on DNMT3A mutated acute myelogenous leukemia, meanwhile, it is found that DNMT3A mutated acute myelogenous leukemia cells have drug resistance to cytarabine, and the gabapentin and the cytarabine are combined to have a synergistic effect on the DNMT3A mutated acute myelogenous leukemia. The discovery of the application provides a new thought and direction for treatment of mutant leukemia, especially acute myelogenous leukemia with DNMT3A mutation.

The application discloses a small-molecule twin drug compound with synergistic analgesic effect, a pharmaceutical composition, a preparation method and application thereof. The twin drug molecule is formed by covalently connecting a drug A and a drug B, wherein the drug A is nefopam, and the drug B is gamma-aminobutyric acid (GABA) and an analogue thereof, including gabapentin, pregabalin, GABA, methoxycarbonyl-gamma-aminobutyric acid (MGB), and cligabalin. The analgesic efficacy of the twin drug molecule is superior to that of combined administration and single drug, the twin drug molecule can obviously improve various acute and chronic inflammatory pains and relieve peripheral neuropathic pain induced by paclitaxel, has higher anti-inflammatory activity than that of combined administration and single drug, and thus has the potential to treat pain, inflammation and inflammation-related diseases, and can effectively reduce the interaction between drugs and increase the medication compliance of patients.